Volume 15, Issue 10 (12-2017)                   IJRM 2017, 15(10): 619-624 | Back to browse issues page

XML Persian Abstract Print

Download citation:
BibTeX | RIS | EndNote | Medlars | ProCite | Reference Manager | RefWorks
Send citation to:

Zohrabi M, Rahmani E, Motamed N, Akbarzadeh S. CXC Ligand 5 cytokine serum level in women with polycystic ovary syndrome and normal body mass index: A case-control study. IJRM. 2017; 15 (10) :619-624
URL: http://journals.ssu.ac.ir/ijrmnew/article-1-868-en.html
1- The Persian Gulf Tropical Medicine Research Center, Bushehr University of Medical Sciences, Bushehr, Iran
2- Department of Obstetrics and Gynecology, Faculty of Medicine, Bushehr University of Medical Sciences, Bushehr, Iran
3- Department of Community Medicine, Faculty of Medicine, Bushehr University of Medical Sciences, Bushehr, Iran
4- Department of Biochemistry, Faculty of Medicine, Bushehr University of Medical Sciences, Bushehr, Iran , Smdakbarzadeh@yahoo.com
Abstract:   (1119 Views)
Background: Polycystic ovary syndrome (PCOS) is the most common endocrine disease and associated with insulin resistance. CXC Ligand 5 (CXCL5) is a new cytokine which is secreted from white adipose tissue during obesity and by blocking insulin signaling pathway inhibits the activity of insulin and promotes insulin resistance.
Objective: The aim of this study was to assess serum level of CXCL5 in PCOS women with normal body mass index.
Materials and Methods: In this case-control study, 30 PCOS women with normal body mass index as the case group and 30 non-PCOS women as the controls were enrolled. Serum levels of CXCL5, insulin and other hormones factors related with PCOS were measured by ELISA method, also the biochemical parameters were measured by autoanalyzer.
Results: Significant increases in serum insulin concentration, homeostasis model assessments of insulin resistance, luteinizing hormone, luteinizing hormone/follicle-stimulating hormone, fasting blood sugar, testosterone, and prolactin were observed in the case group compared to the controls. were in the serum level of CXCL5, cholesterol, low-density lipoprotein-cholesterol, high-density lipoprotein-cholesterol,dehydroepiandrosterone-sulfate, creatinine, and homeostasis model assessment of beta cell function between these two groups.
Conclusion: In this study, no significant change was observed in serum concentrations of CXCL5 in PCOS women with normal BMI.
Full-Text [PDF 441 kb]   (227 Downloads) |   |   Full-Text (HTML)  (71 Views)  
Type of Study: Original Article |

1. Eftekhar T, Sohrabvand F, Zabandan N, Shariat M, Haghollahi F, Ghahghaei-Nezamabadi A. Sexual dysfunction in patients with polycystic ovary syndrome and its affected domains. Iran J Reprod Med 2014; 12: 539-546.
2. Nadjarzadeh A, Dehghani Firouzabadi R, Vaziri N, Daneshbodi H, Lotfi MH, Mozaffari-Khosravi H. The effect of omega-3 supplementation on androgen profile and menstrual status in women with polycystic ovary syndrome: A randomized clinical trial. Iran J Reprod Med 2013; 11: 665-672.
3. Sirmans SM, Pate KA. Epidemiology, diagnosis, and management of polycystic ovary syndrome. Clin Epidemiol 2013; 6: 1-13. [DOI:10.2147/CLEP.S37559]
4. The Rotterdam ESHRE/ASRM‐sponsored PCOS consensus workshop group. Revised 2003 consensus on diagnostic criteria and long-term health risks related to polycystic ovary syndrome. Hum Reprod 2004; 19: 41-47. [DOI:10.1093/humrep/deh098]
5. Akbarzadeh S, Ghasemi S, Kalantarhormozi M, Nabipour I, Abbasi F, Aminfar A, et al. Relationship among plasma adipokines, insulin and androgens level as well as biochemical glycemic and lipidemic markers with incidence of PCOS in women with normal BMI. Gynecol Endocrinol 2012; 28: 521-524. [DOI:10.3109/09513590.2011.650747]
6. Wild RA, Painter PC, Coulson PB, Carruth KB, Ranney GB. Lipoprotein lipid concentrations and cardiovascular risk in women with polycystic ovary syndrome. J Clin Endocrinol Metab 1985; 61: 946-951. [DOI:10.1210/jcem-61-5-946]
7. Wang HS, Wang TH. Polycystic Ovary Syndrome (PCOS), Insulin Resistance and Insulin-Like Growth Factors (IGFs)/IGF-Binding Proteins (IGFBPs). Chang Gung Med J 2003; 26: 540-553.
8. Dunaif A, Xia J, Book CB, Schenker E, Tang Z. Excessive insulin receptor serine phosphorylation in cultured fibroblasts and in skeletal muscle. A potential mechanism for insulin resistance in the polycystic ovary syndrome. J Clin Invest 1995; 96: 801-810. [DOI:10.1172/JCI118126]
9. Ehrmann DA, Barnes RB, Rosenfield RL. Polycystic ovary syndrome as a form of functional ovarian hyperandrogenismdue to dysregulation of androgen secretion. Endocr Rev 1995; 16: 322-353. [DOI:10.1210/er.16.3.322]
10. Dunaif A. Insulin resistance and the polycystic ovary syndrome: mechanism and implications for pathogenesis. Endocr Rev 1997; 18: 774-800. [DOI:10.1210/er.18.6.774]
11. Bremer AA, Miller WL. The serine phosphorylation hypothesis of polycystic ovary syndrome: a unifying mechanism for hyperandrogenemia and insulin resistance. Fertil Steril 2008; 89: 1039-1048. [DOI:10.1016/j.fertnstert.2008.02.091]
12. Chavey C, Lazennec G, Lagarrigue S, Clapé C, Iankova I, Teyssier J, et al. CXCL5 is an adipose tissue derived factor that links obesity to insulin resistance. Cell Metab 2009; 9: 339-349. [DOI:10.1016/j.cmet.2009.03.002]
13. Tacke F, Zimmermann HW, Trautwein C, Schnabl B. CXCL5 plasma levels are decreased in patients with chronic liver Disease. J Gastroenterol Hepatol 2011; 26: 523-529. [DOI:10.1111/j.1440-1746.2010.06436.x]
14. Chavey C, Fajas L. CXCL5 drives obesity to diabetes and further. Aging (Albany NY) 2009; 1: 674-677. [DOI:10.18632/aging.100064]
15. Starr R, Willson TA, Viney EM, Murray LJ, Rayner JR, Jenkins BJ, et al. A family of cytokine-inducible inhibitors of signalling. Nature 1997; 387: 917-921. [DOI:10.1038/43206]
16. Yao L, Herlea-Pana O, Heuser-Baker J, Chen Y, Barlic-Dicen J. Roles of the chemokine system in development of obesity, insulin resistance, and cardiovascular disease. J Immunol Res 2014; 2014: 181450. [DOI:10.1155/2014/181450]
17. Friedwald WT, Levy RT, Frederickson DS. Estimation of the concentration of low-density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge. Clin Chem 1972; 18: 499-502.
18. Chutia H, Lynrah KG. Association of serum magnesium deficiency with insulin resistance in type 2 diabetes mellitus. J Lab Physicians 2015; 7: 75-78. [DOI:10.4103/0974-2727.163131]
19. Nasrat H, Patra SK, Goswami B, Jain A, Raghunandan C. Study of association of leptin and insulin resistance markers in patients of PCOS. Indian J Clin Biochem 2016; 31: 104-107. [DOI:10.1007/s12291-015-0499-8]
20. Kyaw Tun T, McGowan A, Phelan N, Correia N, Boran G, O'Connor AL, et al. Obesity and insulin resistance are the main determinants of postprandial lipoprotein dysmetabolism in polycystic ovary syndrome. Int J Endocrinol 2016; 2016: 9545239. [DOI:10.1155/2016/9545239]
21. Layegh P, Mousavi Z, Farrokh Tehrani D, Parizadeh SM, Khajedaluee M. Insulin resistance and endocrine-metabolic abnormalities in polycystic ovarian syndrome: Comparison between obese and non-obese PCOS patients. Int J Reprod Biomed 2016; 14: 263-270.
22. Chen MJ, Chou CH, Chen SU, Yang WS, Yang YS, Ho HN. The effect of androgens on ovarian follicle maturation: Dihydrotestosterone suppress FSH-stimulated granulosacell proliferation by upregulating PPARγ-dependent PTEN Expression. Sci Rep 2015; 5: 18319. [DOI:10.1038/srep18319]
23. Sharquie KE, Al-Bayatti AA, Al-Ajeel AI, Al-Bahar AJ, Al-Nuaimy AA. Free testosterone, luteinizing hormone/follicle stimulating hormone ratio and pelvic sonography in relation to skin manifestations in patients with polycystic ovary syndrome. Saudi Med J 2007; 28: 1039-1043.
24. Azziz R, Carmina E, Dewailly D, Diamanti-Kandarakis E, Escobar-Morreale HF, Futterweit W, et al. Positions statement: criteria for defining polycystic ovary syndrome as a predominantly hyperandrogenic syndrome: an androgen excess society guideline. J Clin Endocrinol Metab 2006; 91: 4237-4245. [DOI:10.1210/jc.2006-0178]
25. Laganà AS, Rossetti P, Buscema M, La Vignera S, Condorelli RA, Gullo G, et al. Metabolism and ovarian function in PCOS women: A therapeutic approach with inositols. Int J Endocrinol 2016; 2016: 6306410. [DOI:10.1155/2016/6306410]
26. Kumar AN, Naidu JN, Satyanarayana U, Ramalingam K, Anitha M. Metabolic and endocrine characteristics of Indian women with polycystic ovary syndrome. Int J Fertil Steril 2016; 10: 22-28.
27. Nizam K, Memon N, Devrajani BR. Outcome of treatment with lisuride in hyperprolactinemic infertile women. J Liaquat Uni Med Health Sci 2008; 7: 120-123. [DOI:10.22442/jlumhs.08720158]
28. Eftekhar M, Khalili MA, Rahmani E. The efficacy of recombinant versus urinary HCG in ART outcome. Iran J Reprod Med 2012; 10: 543-548.
29. Aflatoonian A, Rahmani E, Rahsepar M. Assessing the efficacy of aspiration and ethanol injection in recurrent endometrioma before IVF cycle: A randomized clinical trial. Iran J Reprod Med 2013; 11: 179-184.
30. Eftekhar M, Dehghani Firouzabadi R, Karimi H, Rahmani E. Outcome of cryopreserved-thawed embryo transfer in the GnRH agonist versus antagonist protocol. Iran J Reprod Med 2012; 10: 297-302.
31. Kalsum A, Jalali S. Role of hyperprolactinemia in fertility. Pak J Med Res 2002; 41: 94-100.پ
32. Neels JG, Badeanlou L, Hester KD, Samad F. Keratinocyte-derived chemokine in obesity: expression, regulation, and role in adipose macrophage infiltration and glucose homeostasis. J Biol Chem 2009; 284: 20692-20698. [DOI:10.1074/jbc.M109.018556]

Add your comments about this article : Your username or Email:

Send email to the article author

© 2020 All Rights Reserved | International Journal of Reproductive BioMedicine

Designed & Developed by : Yektaweb